Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs

被引：131

作者：

Ammi, Rachid ^{[1
]}

De Waele, Jorrit ^{[2
]}

Willemen, Yannick ^{[3
]}

Van Brussel, Ilse ^{[1
]}

Schrijvers, Dorien M. ^{[1
]}

Lion, Eva ^{[3
,4
]}

Smits, Evelien L. J. ^{[2
,3
,4
]}

机构：

[1] Univ Antwerp, Lab Physiopharmacol, B-2610 Antwerp, Belgium

[2] Univ Antwerp VIB, Oncol Res Ctr, B-2610 Antwerp, Belgium

[3] Univ Antwerp, Vaccine & Infect Dis Inst VAXINFECTIO, Lab Expt Hematol, Tumor Immunol Grp, B-62650 Edegem, Belgium

[4] Univ Antwerp Hosp, Ctr Cell Therapy & Regenerat Med, B-2650 Edegem, Belgium

来源：

PHARMACOLOGY & THERAPEUTICS | 2015年 / 146卷

关键词：

Poly(I:C); Poly-ICLC; Cancer vaccine; Adjuvant; TLR; Anti-tumor immunity; TOLL-LIKE RECEPTOR-3; POLYRIBOINOSINIC-POLYRIBOCYTIDYLIC ACID; T-CELL RESPONSES; NK CELLS; POLYCYTIDYLIC ACID; DENDRITIC CELLS; PHASE-I; OVARIAN-CANCER; L-LYSINE; COMBINED IMMUNIZATION;

D O I：

10.1016/j.pharmthera.2014.09.010

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Although cancer vaccination has yielded promising results in patients, the objective response rates are low. The right choice of adjuvant might improve the efficacy. Here, we review the biological rationale, as well as the preclinical and clinical results of polyinosinic:polycytidylic acid and its derivative poly-ICLC as cancer vaccine adjuvants. These synthetic immunological danger signals enhanced vaccine-induced anti-tumor immune responses and contributed to tumor elimination in animal tumor models and patients. Supported by these results, poly-ICLC-containing cancer vaccines are currently extensively studied in the ongoing trials, making it highly plausible that poly-ICLC will be part of the future approved cancer immunotherapies. (C) 2014 Elsevier Inc. All rights reserved.

引用

页码：120 / 131

页数：12

共 115 条

[21] Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant:: therapeutic activity against human cervical cancer in a rodent model [J].

Cui, Zhengrong ;

Qiu, Fu .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (10) :1267-1279

[22] A subset of toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells [J].

Datta, SK ;

Redecke, V ;

Prilliman, KR ;

Takabayashi, K ;

Corr, M ;

Tallant, T ;

DiDonato, J ;

Dziarski, R ;

Akira, S ;

Schoenberger, SP ;

Raz, E .

JOURNAL OF IMMUNOLOGY, 2003, 170 (08) :4102-4110

[23] RETRACTED: Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome (Retracted Article) [J].

Delaloye, Julie ;

Roger, Thierry ;

Steiner-Tardivel, Quynh-Giao ;

Le Roy, Didier ;

Reymond, Marlies Knaup ;

Akira, Shizuo ;

Petrilli, Virginie ;

Gomez, Carmen E. ;

Perdiguero, Beatriz ;

Tschopp, Juerg ;

Pantaleo, Giuseppe ;

Esteban, Mariano ;

Calandra, Thierry .

PLOS PATHOGENS, 2009, 5 (06)

[24] Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205 [J].

Dhodapkar, Madhav V. ;

Sznol, Mario ;

Zhao, Biwei ;

Wang, Ding ;

Carvajal, Richard D. ;

Keohan, Mary L. ;

Chuang, Ellen ;

Sanborn, Rachel E. ;

Lutzky, Jose ;

Powderly, John ;

Kluger, Harriet ;

Tejwani, Sheela ;

Green, Jennifer ;

Ramakrishna, Venky ;

Crocker, Andrea ;

Vitale, Laura ;

Yellin, Michael ;

Davis, Thomas ;

Keler, Tibor .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (232)

[25] Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice [J].

Domingos-Pereira, S. ;

Decrausaz, L. ;

Derre, L. ;

Bobst, M. ;

Romero, P. ;

Schiller, J. T. ;

Jichlinski, P. ;

Nardelli-Haefliger, D. .

MUCOSAL IMMUNOLOGY, 2013, 6 (02) :393-404

[26] Adjuvants for cancer vaccines [J].

Dubensky, Thomas W., Jr. ;

Reed, Steven G. .

SEMINARS IN IMMUNOLOGY, 2010, 22 (03) :155-161

[27]

Durand V., 2006, VACCINE S2, V24

[28] Toll-like receptor expression in murine DC subsets:: lack of TLR7 expression by CD8α+ DC correlates with unresponsiveness to imidazoquinolines [J].

Edwards, AD ;

Diebold, SS ;

Slack, EMC ;

Tomizawa, H ;

Hemmi, H ;

Kaisho, T ;

Akira, S ;

Sousa, CR .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (04) :827-833

[29]

EWEL CH, 1992, CANCER RES, V52, P3005

[30] EVALUATION OF TOPICAL POLYINOSINIC ACID-POLYCYTIDYLIC ACID IN TREATMENT OF LOCALIZED HERPES-ZOSTER IN CHILDREN WITH CANCER - RANDOMIZED, DOUBLE-BLIND CONTROLLED-STUDY [J].

FELDMAN, S ;

HUGHES, WT ;

DARLINGTON, RW ;

KIM, HK .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1975, 8 (03) :289-294

← 1 2 3 4 5 6 7 8 9 10 →